clinical trial · NCT07551492
A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease
Fujian Shengdi Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 9,262
Atherosclerotic Cardiovascular DiseaseHRS9531HRS9531 placebo
brief summary
The purpose of the study is to evaluate the impact of HRS9531 on major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease. This study adopts an event-driven design and ends when the target number of the primary endpoint event is reached.
started
May 1, 2026
primary completion
May 1, 2031
completion
Jun 1, 2031
last updated
Apr 24, 2026
official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Participants With Atherosclerotic Cardiovascular Disease (ASCVD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol